Searching News Database: orphan drug designation
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
HSMN NewsFeed - 31 May 2024
SIFI Receives Positive CHMP Opinion for Akantior(R) (polihexanide 0.08%) in Acanthamoeba Keratitis
SIFI Receives Positive CHMP Opinion for Akantior(R) (polihexanide 0.08%) in Acanthamoeba Keratitis
HSMN NewsFeed - 30 May 2024
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
HSMN NewsFeed - 14 May 2024
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 20 Nov 2023
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
HSMN NewsFeed - 6 Jan 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
HSMN NewsFeed - 24 Aug 2022
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
HSMN NewsFeed - 16 Jun 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
HSMN NewsFeed - 5 Apr 2021
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
HSMN NewsFeed - 30 Mar 2021
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
HSMN NewsFeed - 17 Mar 2021
Peptilogics Strengthens Leadership Team with Three Strategic Appointments
Peptilogics Strengthens Leadership Team with Three Strategic Appointments
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 11 Jun 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
HSMN NewsFeed - 3 Mar 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 29 Jan 2020
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 20 Jun 2019
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
HSMN NewsFeed - 29 Jan 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
HSMN NewsFeed - 25 Sep 2018
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
HSMN NewsFeed - 17 Sep 2018
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
HSMN NewsFeed - 30 Jan 2018
FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly
FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly
HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
HSMN NewsFeed - 26 Dec 2017
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
HSMN NewsFeed - 13 Dec 2017
Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics
Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics
HSMN NewsFeed - 27 Nov 2017
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
HSMN NewsFeed - 16 Nov 2017
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
HSMN NewsFeed - 31 Oct 2017
Mitosol(R)'s Orphan Drug Designation is Expanded for All Glaucoma Surgery
Mitosol(R)'s Orphan Drug Designation is Expanded for All Glaucoma Surgery
HSMN NewsFeed - 6 Oct 2017
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
HSMN NewsFeed - 5 Sep 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 6 Jul 2017
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
HSMN NewsFeed - 25 Apr 2017
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
HSMN NewsFeed - 17 Apr 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
HSMN NewsFeed - 15 Feb 2017
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 29 Nov 2016
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Conditional Approval from the European Commission to Treat Multiple Myeloma
HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
HSMN NewsFeed - 20 Sep 2016
Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera(R)
Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera(R)
HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 4 Aug 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
HSMN NewsFeed - 28 Jul 2016
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
HSMN NewsFeed - 29 Jun 2016
Biostage Files for FDA Orphan Drug Designation for Cellspan(TM) Esophageal Implant
Biostage Files for FDA Orphan Drug Designation for Cellspan(TM) Esophageal Implant
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 17 May 2016
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 15 Mar 2016
Heart Metabolics Announces Multiple Senior Appointments To Management Team
Heart Metabolics Announces Multiple Senior Appointments To Management Team
HSMN NewsFeed - 26 Feb 2016
Catalyst Pharmaceuticals Appoints Brian Elsbernd as Senior Vice President of Legal and Compliance
Catalyst Pharmaceuticals Appoints Brian Elsbernd as Senior Vice President of Legal and Compliance
HSMN NewsFeed - 17 Feb 2016
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
HSMN NewsFeed - 23 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
HSMN NewsFeed - 21 Jan 2016
vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury
vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury
HSMN NewsFeed - 19 Jan 2016
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
HSMN NewsFeed - 12 Jan 2016
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
HSMN NewsFeed - 15 Sep 2015
Makindus Bolsters Management Team with Appointment of Michael Celano as Chief Financial Officer
Makindus Bolsters Management Team with Appointment of Michael Celano as Chief Financial Officer
HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 18 Feb 2015
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris(TM) in FSHD
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris(TM) in FSHD
HSMN NewsFeed - 5 Jan 2015
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 4 Sep 2014
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
HSMN NewsFeed - 5 Aug 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
HSMN NewsFeed - 23 Jul 2014
FDA Approves Eagle Pharmaceuticals’ Ryanodex(R) for the Treatment of Malignant Hyperthermia
FDA Approves Eagle Pharmaceuticals’ Ryanodex(R) for the Treatment of Malignant Hyperthermia
HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
HSMN NewsFeed - 17 Apr 2014
Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing
Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing
HSMN NewsFeed - 16 Apr 2014
OxThera AB Receives SEK 70 Million Financing to Continue its Key Clinical Programs
OxThera AB Receives SEK 70 Million Financing to Continue its Key Clinical Programs
HSMN NewsFeed - 26 Mar 2014
FDA Approves Optiguide(R) DCYL700 Fiber Optic Diffuser Series Flexible Fiber
FDA Approves Optiguide(R) DCYL700 Fiber Optic Diffuser Series Flexible Fiber
HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
HSMN NewsFeed - 3 Jan 2014
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
HSMN NewsFeed - 3 Jan 2014
RegeneRx Receives Orphan Drug Designation for Tβ4 in the Treatment of Neurotrophic Keratopathy
RegeneRx Receives Orphan Drug Designation for Tβ4 in the Treatment of Neurotrophic Keratopathy
HSMN NewsFeed - 24 Dec 2013
Concordia Healthcare Corp. Announces Acquisition Of Pinnacle Biologics, Inc.
Concordia Healthcare Corp. Announces Acquisition Of Pinnacle Biologics, Inc.
HSMN NewsFeed - 20 Dec 2013
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
HSMN NewsFeed - 27 Nov 2013
CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
HSMN NewsFeed - 30 Sep 2013
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
HSMN NewsFeed - 31 Jul 2013
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
HSMN NewsFeed - 24 Jul 2013
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
HSMN NewsFeed - 4 Mar 2013
Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer
Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer
HSMN NewsFeed - 24 Jan 2013
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
HSMN NewsFeed - 21 Nov 2012
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
HSMN NewsFeed - 4 Oct 2012
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
HSMN NewsFeed - 20 Jul 2012
First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
HSMN NewsFeed - 25 Jun 2012
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
HSMN NewsFeed - 22 Jun 2012
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive(R)) for Patients with Short Bowel Syndrome
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive(R)) for Patients with Short Bowel Syndrome
HSMN NewsFeed - 13 Jun 2012
Stratatech’s StrataGraft(R) Skin Substitute Granted FDA Orphan Drug Designation
Stratatech’s StrataGraft(R) Skin Substitute Granted FDA Orphan Drug Designation
HSMN NewsFeed - 19 Mar 2012
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
HSMN NewsFeed - 12 Mar 2012
HemaQuest Pharmaceuticals Raises $13 Million in Series B Extension Financing
HemaQuest Pharmaceuticals Raises $13 Million in Series B Extension Financing
HSMN NewsFeed - 18 Jan 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
HSMN NewsFeed - 4 Jan 2012
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
HSMN NewsFeed - 7 Dec 2011
Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking
Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking
HSMN NewsFeed - 1 Jun 2011
FDA Grants Orphan Drug Designation for XTL's rHuEPO Treatment for Multiple Myeloma
FDA Grants Orphan Drug Designation for XTL's rHuEPO Treatment for Multiple Myeloma
HSMN NewsFeed - 9 May 2011
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
HSMN NewsFeed - 8 Mar 2011
Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
HSMN NewsFeed - 2 Mar 2011
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
HSMN NewsFeed - 25 Feb 2011
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
HSMN NewsFeed - 14 Feb 2011
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program
HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
Additional items found! 293
Members Archive contains
293 additional stories matching:
orphan drug designation
(Password required)
orphan drug designation
(Password required)